Globenewswire·2025-12-19 21:15Core Viewpoint - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the upcoming lead plaintiff deadline for a class action lawsuit, indicating potential compensation for affected investors [1]. Group 1: Class Action Details - The class action pertains to securities purchased between November 4, 2024, and October 3, 2025, with a lead plaintiff deadline set for January 16, 2026 [1]. - Investors who purchased Skye securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [3]. Group 3: Case Allegations - The lawsuit alleges that Skye Bioscience's defendants made materially false and misleading statements regarding the effectiveness and prospects of their product, nimacimab, leading to investor damages when the truth was revealed [4].